Small Cap Feast
Small Cap Feast – 15 February 2021
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
AMTE Power, a developer and manufacturer of lithium-ion battery cells for specialist markets, announced its intention to seek admission to trading on AIM. Admission is expected to take place during March 2021. The Company intends to raise approximately £7 million by way of a placing of new ordinary shares in the capital of the Company. Timing TBC.
Samarkand Group Limited, the cross-border eCommerce technology and retail group opening up the world’s largest market for brands and retailers, intends to IPO on the Apex Segment Aquis Stock Exchange Growth Market. Admission is targeted for March 2021.
Cellular Goods a UK-based provider of premium consumer products based on biosynthetic cannabinoids announced its intention to join the main market (standard) this Spring. Target valuation £20m raising c. £8m “to finalise the development and launch of a range of the Company’s premium-quality consumer products based on biosynthetic cannabinoids, which is fully compliant under UK law.”
Kanabo Group (RTO by Spinnaker Opportunities SOP.L) on the main market (standard). Raising £6m, enlarged mkt cap £23.4m. Kanabo focuses on the distribution of Cannabis-derived products for medical patients, and non-THC products for CBD consumers . Due 16 Feb.
NextEnergy Renewables to launch an IPO on the Main Market. NREN is a differentiated renewables investment company that aims to capture the most attractive private renewables and energy transition infrastructure investment opportunities globally. Targeting a £300m raise. NREN is targeting total returns of 9-11 per cent. per annum (net of all fees and expenses but including the Target Dividend and capital appreciation) . The Company’s target dividend yield for the first full financial year to 31 December 2022 is 5.5 pence. Due Early March 2021.
Auction Technology Group is considering an IPO on the Main Market. The Group operates six world-leading online Marketplaces and proprietary global auction platform technology for curated online auctions . In FY20 the Group delivered pro forma revenue of £52.3 million, supported by notable underlying year-on-year growth from both Standalone ATG Group and Standalone Proxibid Group (12.4 per cent. and 40.4 per cent., respectively). For the same period, the Group delivered a strong profitability performance of £22.3 million pro forma Adjusted EBITDA representing a pro forma Adjusted EBITDA margin of 42.6 per cent. Expected March 2021.
Digital 9 Infrastructure launch an initial public offering on the Specialist Fund Segment of the Main Market of the London Stock Exchange, by way of an initial placing and offer for subscription for a target issue £400m. Digital 9 Infrastructure plc is a newly established, externally managed investment trust. The Company will invest in a range of digital infrastructure assets which deliver a reliable, functioning internet. The IPO Prospectus is expected to be published in March 2021.
Cordiant Digital Infrastructure to admit its shares on the Specialist Fund Segment of the Main Market of the London Stock Exchange . Targeting a £300m raise. Cordiant invests in global infrastructure and real assets, running infrastructure private equity and infrastructure private credit strategies through limited partnership funds and managed accounts. Due 16 Feb.
4basebio UK Societas is a specialist life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. The Company has been divested from 4basebio AG , a German company listed on the Prime Standard segment of the Frankfurt Stock Exchange . No capital to be raised on Admission. Anticipated market capitalisation on AIM Admission: £14.53m. Due 17 Feb
Cornish Metals (TSX-V: CUSN) intends to list on AIM. The Company is proposing to raise £5m by way of private placement of new Common Shares to advance the United Downs copper-tin project. The Company expects that Admission will become effective 16 February 2021. The Company’s Common Shares will continue to be listed and trade on the TSX-V in Canada. Raising £8.2m. £18.7m mkt cap.
Microsaic Systems 0.275p £16.7m (MSYS.L)
The micro-engineering, miniaturised chip-based mass spectrometry producer for point-of-need analytical detection, has signed a non-binding Heads of Terms with DeepVerge plc (AIM: DVRG) to enter a multi-year Framework Services Agreement. Under the Agreement, which is expected to be signed on or before 31 March 2021, Microsaic will supply miniaturised mass spectrometry equipment and services on a non-exclusive basis across DeepVerge’s sales, marketing and distribution channels for quality and contamination detection in a range of markets. These include Human, Environmental Health and Diversified Industries, including point of need and laboratory solutions in, chemical, bio chemical, biofuel, biodegradable plastic, biologics and waste-water treatment industries .
Under this Agreement, Microsaic will transition its business model to a revenue-sharing, collaborative and commercial partnership strategy. The Heads of Terms include provision for an initial order by DeepVerge for two units, each worth £50,000, plus a commitment of up to £150,000 by DeepVerge plc to install pilot facilities in DeepVerge’s York laboratories . Under the Agreement, Microsaic shall pay to DeepVerge a commission based on the revenues received from customers introduced by DeepVerge.
Surgical Innovations Group 2.15p £20.01m (SUN.L)
The designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery (“MIS”), announces a new USA distribution agreement with Microline Surgical Inc. (“Microline”) for the Company’s range of YelloPort+PlusTM and YelloPort EliteTM Access Devices. The 5-year agreement brings a significant opportunity to SI for growth in the US Trocar market.
Microline’s sales & marketing structure is ideally placed to leverage their experience with Resposable surgical instruments to effectively drive US sales of YelloPort+PlusTM and YelloPort EliteTM Access Devices.
Physiomics* 8.2p £8m (PYC.L)
The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, it has entered into a new agreement with ValiRx plc (AIM:VAL), a clinical stage drug development company. The new agreement supersedes the agreement between Physiomics and ValiRx which was announced on 13 September 2011. Under the terms of the new agreement, ValiRx will benefit from Physiomics’ experience in modelling the effects of prostate cancer treatment, as well the use of the latest version of its Virtual Tumour™ technology, which will be applied to derive valuable information from the additional data generated by the completed clinical trial of VAL201. Physiomics will also support ValiRx in modelling the use of the VAL201 peptide in endometriosis (VAL301) and Coronavirus (BC201).
Physiomics has developed a quantitative systems pharmacology approach that uses pre-clinical and clinical data to model the activity of a drug candidate. This data can be used to explore the mechanism of action, disease impact and optimal dosing strategies.
Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection. Eligibility for part of this fee will be conditional on completion of an agreed programme of work by Physiomics that builds on the work already carried out under the 2011 agreement. This programme of work will start on 15 February 2021 and is required to be completed by 15 November 2021. In recognition of the collaborative nature of this new agreement, Physiomics will also be offered a seat on the ValiRx scientific advisory board.
Strategic Minerals 0.525p £10m (SML.L)
Its 100% owned subsidiary Cornwall Resources Limited (CRL) has been notified that the ‘Deep Digital Cornwall’ project led by the University of Exeter’s Camborne School of Mines (CSM), in which CRL and Cornish Lithium are delivery partners, has been awarded funding by the European Regional Development Fund (ERDF), through HM Ministry of Housing, Communities, and Local Government (HMCLG). Highlights:
- Redmoor exploration licence area will be used as a field laboratory for collection of geochemical and geophysical data, which will also provide CRL with information relevant to a number of new prospects within its Mineral Rights.
- CRL to receive up to £446,063 of grant funding for its part in the project from the ERDF, in return for a contribution from CRL of 20% (from existing budget).
- Strong alignment with CRL’s objectives for Redmoor, one of which is the continued expansion of its understanding of the geology at this highly prospective site.
- CRL to benefit from access to international-level research and collaboration concerning the use of digital exploration data, through CSM.
- Positive support for Cornwall and its natural resources sector from HMCLG and ERDF.
Ebiquity 20.9p £17.3m (EBQ.L)
The independent marketing and media consultancy, announces a pre-close trading update for the financial year ended 31 December 2020, ahead of the preliminary results announcement planned for 25 March 2021.
Ebiquity’s trading for the year ended 31 December 2020 was in line with the Board’s expectations with higher revenue in the second half of the year than in the first. This reflected both the recovery in demand from existing clients as they returned to more normal activity levels, and success in winning new business. As expected, the Group returned to profitability in the second half, although it is likely to report a small adjusted operating loss for the full year.
Additionally, the Group’s net debt of £7.7 million as at 31 December 2020 was in line with expectations.
Synairgen 193p £386m (SNG.L)
The respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase II/III trial, evaluating patients with mild to moderate COVID-19 symptoms not yet requiring hospitalisation.
Advance Energy SUSPENDED (ADV.L)
The energy company seeking growth through acquisition or farm-in to non-operated interests in discovered upstream projects, updated on the Buffalo oil field. Carnarvon Petroleum Limited (ASX:CVN, Carnarvon), has announced today the award of a drilling management services contract to Petrofac Limited (LSE: PFC) for the B-10 appraisal well, which is expected to be drilled in H2 2021, subject to funding, rig availability and government approvals.
On 17 December 2020, the Company announced it had entered into a subscription agreement with Timor-Leste Petroleum Pty Ltd (a subsidiary of Carnarvon) to obtain up to a 50% equity interest in Carnarvon Petroleum Timor, Unipessoal Lda (JVco), its subsidiary which holds a 100% working interest in the Buffalo oil field, conditional, inter alia, on raising the necessary funding. JVco is presently making drilling preparations for the B-10 appraisal well, which is designed to drill the crest of the structure with the objectives of re-certifying resources into reserves and finalising the development plan for this proven oil field.
Following a tender process, Carnarvon made the decision to award the drilling management services contract to Petrofac, which will include completion of detailed well design, procurement of long lead items and contracting the drilling rig and associated services, including a shore based location. Pursuant to the Subscription Agreement, Advance Energy provided approval for the contract award. Drilling of the B-10 appraisal well is anticipated to occur in H2 2021.
Learning Tech 175.15p £1,295m (LTG.L)
The provider of services and technologies for digital learning and talent management, has agreed to acquire getBridge LLC and related assets, a leading learning and talent development software provider, from Instructure Inc for a cash consideration of $50.0 million (c.£36.1 million). Bridge is a learning, performance and skills development platform for mid-enterprise organisations, headquartered in the US with operations in the UK and Hungary.
The acquisition of Bridge significantly extends LTG’s mid-enterprise learning and talent offering. Bridge is highly complementary to PeopleFluent, which serves the large enterprise market, and BreezyHR, which serves the small and medium-sized business market. The acquisition is strategically important because it enables LTG to provide a holistic learning and talent development offering to meet the needs of small, mid-size and large enterprises, three distinct groups with varying requirements. The combination and integration of Bridge with LTG’s other portfolio offerings, including the recently acquired Reflektive engagement and analytics platform, will create opportunities for cross-sell and upsell-led growth within the Group.
Bridge achieved unaudited revenue of c.$21.0 million in FY20, of which more than 90% was derived from recurring annual and multi-year contracts. It generated an EBITDA loss of c.$1.3 million in the same period. With the operational synergies that will be created with the rest of the Group, LTG expects Bridge to become earnings accretive from H2 2021 and to align with its typical software division margins by early 2022. Bridge has more than 800 customers which combined with LTG’s global customer base represents a compelling cross-selling opportunity.
Netcall 59.5p £87.9m (NET.L)
The provider of intelligent automation and customer engagement software, announced the expansion of its Liberty Platform to include Robotic Process Automation (RPA) capabilities and enhancements to Liberty Create, Liberty Converse and Liberty Connect. This follows the acquisition of RPA vendor Automagica in October 2020 and the completion of the integration and development of its RPA solution to manage processes and automation from a single cloud solution.
The launch of Liberty RPA significantly broadens the Group’s offering into the high growth automation market, providing customers with a comprehensive digital transformation toolkit. Comprising Create, the low-code application platform, Converse, the customer engagement and contact centre solution, Connect, the chatbot and instant digital messaging solution, and now RPA, the Liberty platform is a one-stop shop for process automation and customer engagement.
Sativa Wellness Group 3.6p £10.89m (AQSE:SWEL)
Sativa has submitted its Novel Food application for validation by the Food Standards Agency ahead of the 31 March 2021 deadline, as part of the Company’s ongoing commitment to continually deliver the highest level of regulatory compliance and product quality – ‘CBD you can trust’.
The submission, led by award winning Life Sciences Regulatory and Quality Compliance consultancy, Global Regulatory Services and supported by Group’s in-house team of scientist and quality/compliance professionals, incorporates an extensive array of products under its Goodbody brands and on behalf of white label customers. Products include oil-based food supplements, gummies, soft gel capsules and sports recovery gels, as well as wholesale bulk CBD ingredients.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.